153.[20230120]KDIGO 2022 Clinical PracticeGuideline for Hepatitis C in…
페이지 정보
작성자 신호식 작성일23-02-03 14:18 조회579회 댓글0건관련링크
-
https://youtu.be/RNQV8OOGQ-k
493회 연결
https://youtu.be/RNQV8OOGQ-k
본문
첨부한 자료(유튜브 클립, 참고문헌 등)를 학문적 목적으로만 사용해 주시길 부탁드립니다
Review Kidney Int
. 2022 Dec;102(6):1228-1237. doi: 10.1016/j.kint.2022.07.012.
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
Paul Martin 1, Ahmed A Awan 2, Marina C Berenguer 3, Annette Bruchfeld 4, Fabrizio Fabrizi 5, David S Goldberg 6, Jidong Jia 7, Nassim Kamar 8, Rosmawati Mohamed 9, Mário Guimarães Pessôa 10, Stanislas Pol 11, Meghan E Sise 12, Ethan M Balk 13, Craig E Gordon 14, Gaelen Adam 13, Michael Cheung 15, Amy Earley 15, Michel Jadoul 16
Affiliations expand
PMID: 36411019 DOI: 10.1016/j.kint.2022.07.012
Free article
Abstract
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.
Keywords: KDIGO; chronic kidney disease; cryoglobulinemia; dialysis; direct-acting antivirals; glomerular diseases; guideline; hemodialysis; hepatitis C virus; infection control; kidney transplantation; liver testing; nosocomial transmission; screening; systematic review.
Review Kidney Int
. 2022 Dec;102(6):1228-1237. doi: 10.1016/j.kint.2022.07.012.
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
Paul Martin 1, Ahmed A Awan 2, Marina C Berenguer 3, Annette Bruchfeld 4, Fabrizio Fabrizi 5, David S Goldberg 6, Jidong Jia 7, Nassim Kamar 8, Rosmawati Mohamed 9, Mário Guimarães Pessôa 10, Stanislas Pol 11, Meghan E Sise 12, Ethan M Balk 13, Craig E Gordon 14, Gaelen Adam 13, Michael Cheung 15, Amy Earley 15, Michel Jadoul 16
Affiliations expand
PMID: 36411019 DOI: 10.1016/j.kint.2022.07.012
Free article
Abstract
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.
Keywords: KDIGO; chronic kidney disease; cryoglobulinemia; dialysis; direct-acting antivirals; glomerular diseases; guideline; hemodialysis; hepatitis C virus; infection control; kidney transplantation; liver testing; nosocomial transmission; screening; systematic review.
